Severe sepsis, a clinical syndrome in patients with infection, surgery, trauma, or other injury, is associated with high mortality and limited effective therapeutics. High mobility group B1 (HMGB1), an endogenous molecule released by macrophages and other immunocompetent cells, is a necessary and sufficient mediator of lethal sepsis. Anti-HMGB1 antibodies that neutralize the cytokine activity of HMGB1 confer significant protection against inflammation, organ damage, and lethality in diverse animal models including severe sepsis, arthritis, pancreatitis, burn injury, acute lung injury, cerebral ischemia, hemorrhagic shock, colitis, and other inflammation and injury syndromes. The central tenet of the HMGB1 paradigm is that it mediates biological functions ranging from activating macrophages to secrete cytokines, to stimulating neutrophil migration. At present there are several major unanswered questions in this field, including: how do post-translational modifications alter HMGB1 interactions with TLR4 and RAGE, its two best understood and pre-eminent receptors? What is the effect of the HMGB1-TLR4 complex on activating intracellular signal transduction that drives cytokine release? Do HMGB1-TLR4 and HMGB1-RAGE complex formation mediate unique biological responses that can be dissociated in the context of sepsis? These questions will be addressed in the following Aims:
Specific Aim 1 : To elucidate whether cysteine modifications influence interaction of HMGB1-RAGE.
Specific Aim 2. To elucidate whether HMGB1-TLR4 activates TIRAP-MyD88 and TRAM-TRIF dependent signaling.
Specific Aim 3. To determine the beneficial effects of HMGB1- TLR4 or HMGB1-RAGE interaction in attenuating disease severity in sepsis. We propose to utilize an innovative strategy based on surface plasmon resonance to study HMGB1 binding to TLR4 and RAGE, substitution of specific amino acids to modify binding and signaling, proximity ligation assays to study intracellular binding of HMGB1 to TLR4 and RAGE, wholly synthetic peptides based on post- translational modified HMGB1 to produce competitive antagonists, and knockout mice to study these significant mechanisms in the context of lethal sepsis.

Public Health Relevance

Severe sepsis is a major public health problem, because it is the leading cause of death in hospitalized patients in the United States, and one of the ten leading causes of death in the developed world. Recent evidence indicates that a protein, HMGB1, produced by the immune system, is a source of potentially lethal toxicity during sepsis. The studies proposed here will determine how HMGB1 activates the cells of the immune system to heighten the risk of death. This study will also analyze effects of HMGB1 antagonists to improve disease severity and survival in animal models of sepsis. This understanding will guide development of drugs to neutralize the toxicity of HMGB1 and prevent the complications of sepsis.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-SBIB-E (02))
Program Officer
Somers, Scott D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Feinstein Institute for Medical Research
United States
Zip Code
Ju, Zhongliang; Chavan, Sangeeta S; Antoine, Daniel J et al. (2014) Sequestering HMGB1 via DNA-conjugated beads ameliorates murine colitis. PLoS One 9:e103992
Lu, Ben; Antoine, Daniel J; Kwan, Kevin et al. (2014) JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A 111:3068-73
Valdes-Ferrer, S I; Rosas-Ballina, M; Olofsson, P S et al. (2013) HMGB1 mediates splenomegaly and expansion of splenic CD11b+ Ly-6C(high) inflammatory monocytes in murine sepsis survivors. J Intern Med 274:381-90
Higgins, Sarah J; Xing, Katharine; Kim, Hani et al. (2013) Systemic release of high mobility group box 1 (HMGB1) protein is associated with severe and fatal Plasmodium falciparum malaria. Malar J 12:105
Yang, Huan; Antoine, Daniel J; Andersson, Ulf et al. (2013) The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 93:865-73
Gero, Domokos; Szoleczky, Petra; Modis, Katalin et al. (2013) Identification of pharmacological modulators of HMGB1-induced inflammatory response by cell-based screening. PLoS One 8:e65994
Bruchfeld, A; Goldstein, R S; Chavan, S et al. (2010) Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis. J Intern Med 268:94-101
Yang, Huan; Tracey, Kevin J (2010) Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799:149-56
Yang, Huan; Hreggvidsdottir, Hulda S; Palmblad, Karin et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 107:11942-7
Tang, D; Kang, R; Cheh, C-W et al. (2010) HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29:5299-310

Showing the most recent 10 out of 21 publications